Novavax (NVAX) Retained Earnings: 2009-2025
Historic Retained Earnings for Novavax (NVAX) over the last 16 years, with Sep 2025 value amounting to -$4.6 billion.
- Novavax's Retained Earnings rose 6.94% to -$4.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.6 billion, marking a year-over-year increase of 6.94%. This contributed to the annual value of -$5.0 billion for FY2024, which is 3.89% down from last year.
- Novavax's Retained Earnings amounted to -$4.6 billion in Q3 2025, which was down 4.62% from -$4.4 billion recorded in Q2 2025.
- Novavax's 5-year Retained Earnings high stood at -$2.1 billion for Q1 2021, and its period low was -$5.0 billion during Q4 2024.
- In the last 3 years, Novavax's Retained Earnings had a median value of -$4.6 billion in 2023 and averaged -$4.7 billion.
- Per our database at Business Quant, Novavax's Retained Earnings crashed by 93.04% in 2021 and then increased by 9.63% in 2025.
- Quarterly analysis of 5 years shows Novavax's Retained Earnings stood at -$3.6 billion in 2021, then fell by 18.19% to -$4.3 billion in 2022, then dropped by 12.75% to -$4.8 billion in 2023, then dropped by 3.89% to -$5.0 billion in 2024, then increased by 6.94% to -$4.6 billion in 2025.
- Its Retained Earnings was -$4.6 billion in Q3 2025, compared to -$4.4 billion in Q2 2025 and -$4.5 billion in Q1 2025.